Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Principal Investigator
Name
Jonathan Hofmann
Degrees
Ph.D., M.P.H.
Institution
NCI
Position Title
Investigator
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-355
Initial CDAS Request Approval
Mar 16, 2018
Title
Evaluating circulating immunologic markers in the development of multiple myeloma
Summary
Severe immune dysregulation is a strong risk factor for multiple myeloma (MM), and experimental studies have implicated chemokines and pro-angiogenic cytokines in MM pathogenesis. We are investigating whether selected circulating immunologic markers are associated with progression from the precursor condition monoclonal gammopathy of undetermined significance (MGUS) to MM in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (EEMS study 2010-145). Specifically, we will conduct analyses to determine if incorporating immune marker measurements can be used to improve existing risk prediction models accounting for established factors.

To accomplish this, we are requesting data on selected demographic and other characteristics of all participants from the screening arm of PLCO, including those with MGUS and MM included in our EEMS study. These data will be used to assign sampling weights for weighted Cox regression models to predict the likelihood of progression from MGUS to MM. We will assess improvements in risk prediction for individual markers as well as a composite marker score based on multiple logistic regression and validated with 5-fold cross-validation (Harrell, 2001) as was previously done to develop an inflammation score that predicts lung cancer risk (Shiels et al, 2015).
Aims

1. To evaluate whether incorporating selected immunologic markers into existing risk stratification models can improve our ability to identify MGUS-positive subjects at high risk of progression to clinically manifest MM.

Collaborators

Mark Purdue
Hormuzd Katki
Ola Landgren

Related Publications